Ensayos clínicos Solicite una Consulta en Mayo Clinic Centros, viajes y alojamientoInvestigación Oct. 10, 2019 Comparte en: FacebookTwitter Mostrar referencias Miller HL. Allscripts EPSi. Mayo Clinic, Rochester, Minn. March 14, 2016. NCI-designated cancer centers. National Cancer Institute. http://www.cancer.gov/research/nci-role/cancer-centers. Accessed April 22, 2016. Mayo Clinic Cancer Center. National Cancer Institute. http://www.cancer.gov/research/nci-role/cancer-centers/find/mayoclinic. Accessed April 22, 2016. Cancer Center of Excellence designation. Florida Department of Health. http://www.floridahealth.gov/provider-and-partner-resources/research/cancer-center-of-excellence-award.html. Accessed April 22, 2016. A continuación se enumeran ensayos clínicos actuales.601 estudios en Oncología (médica) (estudios abiertos únicamente). Filtrar esta lista de estudios según la ubicación, el estado del estudio y más. Cutaneous Lymphoma Database Scottsdale/Phoenix, Ariz. The purpose of this study is to create a long-term, prospective database of cutaneous lymphoma that will lead to a better understanding of the biological behavior of cutaneous lymphomas as well as the effectiveness of interventions. Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer Rochester, Minn., Scottsdale/Phoenix, Ariz. This phase II trial studies how well alisertib with or without fulvestrant works in treating patients with endocrine-resistant breast cancer that has spread to other places in the body. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells or reducing the amount of estrogen made by the body. Giving alisertib with or without fulvestrant may be better in treating patients with breast cancer. Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer Rochester, Minn. This randomized phase II trial studies how well iodine I-131works with or without selumetinib in treating patients with thyroid cancer that has returned or has spread from where it started to other places in the body. Many thyroid cancers absorb iodine. Because of this, doctors often give radioactive iodine (iodine I-131) alone to treat thyroid cancer as part of standard practice. It is thought that the more thyroid tumors are able to absorb radioactive iodine, the more likely it is that the radioactive iodine will cause those tumors to shrink. Selumetinib may help radioactive iodine work better in patients whose tumors still absorb radioactive iodine. It is not yet known whether iodine I-131 is more effective with or without selumetinib in treating thyroid cancer. Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. The primary objective of the study is to determine the safety and tolerability of I-131-CLR1404, with and without concurrent weekly dexamethasone, in patients with relapsed or refractory multiple myeloma who have previously been treated with, or are intolerant of, an immunomodulator and a proteasome inhibitor. Study Using Chromogranin A as Surveillance Biomarker in Patients with cARcinoids Rochester, Minn. The purpose of this study is to monitor and validate the performance and stability of the BRAHMS Chromogranin A (CgA) II KRYPTOR Assay in patients with Gastroentero-pancreatic neuroendocrine tumors (GEP-NETs). Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast cancer. Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. This early phase I trial studies the side effects of ketoconazole and how well it works in treating participants with ongoing EGFR inhibitor-induced rash. Ketoconazole may reduce the symptoms related to EGFR inhibitor therapy and improve EGFR inhibitor-induced rash. A Study to Determine the Best Individualized Cancer Therapy Using Circulating Tumor DNA (ctDNA) in Patients with GI, CNS, and Thoracic Cancers. Jacksonville, Fla. This study proposes to develop and maintain a biorepository of blood samples collected from patients receiving definitive chemoradiotherapy for locally advanced rectal cancer, non-small cell lung cancer, or cervical cancer. The ultimate goal of this biorepository will be to provide the resource to initiate an exploration of ctDNA as a potential liquid biopsy for GI and Thoracic malignancy detection and surveillance. A Study of Circulating Tumor DNA as a Biomarker of a Complete Response of Disease for Advanced Gastroesophageal Adenocarcinoma Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate circulating tumor DNA as a potential biomarker for pre-surgery treatment response in patients who have esophageal cancer. P1101 in Treating Patients With Early Myelofibrosis Scottsdale/Phoenix, Ariz. This pilot phase II trial studies P1101 (polyethyleneglycol [PEG]-proline-interferon alpha-2b) in treating patients with early myelofibrosis. PEG-proline-interferon alpha-2b is a substance that can improve the body's natural response and may slow the growth of early myelofibrosis. Numeración de páginas Estudios clínicos Ir a página 11 Ir a página 22 Ir a página 33 Ir a página 44 Ir a página 55 SiguientePróxima página Mayo Clinic en Minnesota y Mayo Clinic en Phoenix/Scottsdale, Arizona han sido reconocidas entre los mejores hospitales oncológicos del país durante el período 2019-2020 por U.S. News and World Report. Lee más sobre este gran honor. Oncología (médica)Página inicial del departamentoSeccionesSolicita una consultaDescripción generalEnfermedades tratadasMédicosGrupos especializadosConocimientos y categoríasCentros, viajes y alojamientoEnsayos clínicosInvestigaciónExperiencias en Mayo Clinic y nuestros pacientes cuentan su historiaCostos y seguroNoticias de Mayo ClinicRecursos para profesionales en Medicina Investigación: todo es por los pacientes SeccionesSolicita una consultaDescripción generalEnfermedades tratadasMédicosGrupos especializadosConocimientos y categoríasCentros, viajes y alojamientoEnsayos clínicosInvestigaciónExperiencias en Mayo Clinic y nuestros pacientes cuentan su historiaCostos y seguroNoticias de Mayo ClinicRecursos para profesionales en Medicina ORG-20180179 Departamentos y centros Departamentos y centros médicos Oncología (médica)